Last reviewed · How we verify
NCT07010159
Phase 2/3 Study of KPL-387 in Recurrent Pericarditis
Phase 2, PHASE3 trial testing KPL-387 in Pericarditis in 165 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Kiniksa Pharmaceuticals International, plc |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 165 |
| Start date | 25 July 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2029 |
| Sites | 50 locations across France, Italy, Greece, Serbia, United Kingdom, Poland, Canada, United States |
Drugs / interventions tested
- KPL-387 — full drug profile →
- Placebo
Conditions studied
- Pericarditis — all drugs for Pericarditis →
- Pericarditis Acute — all drugs for Pericarditis Acute →
- Recurrent Pericarditis — all drugs for Recurrent Pericarditis →
Sponsor
Kiniksa Pharmaceuticals International, plc — full company profile →
Who can join
Adults 18 to 80, any sex, with Pericarditis or Pericarditis Acute. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07010159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of KPL-387
Trials testing the same drug.
- NCT07288216 — Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · recruiting
Other recruiting trials for Pericarditis
Currently open trials in the same condition.
- NCT07288216 — Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · recruiting
- NCT07468461 — CACP: Study on Camptodactyly - Arthropathy - Coxa Vara - Pericarditis (CACP) Syndrome · recruiting
- NCT05925790 — Clinical Phenotypes in Pericarditis: IL-1RA Antibodies and suPAR Levels · recruiting
- NCT05046002 — COVID-19 Vaccine-induced Inflammatory Heart Disease Prevalence Registry · recruiting
Other Kiniksa Pharmaceuticals International, plc trials
Trials by the same sponsor.
- NCT07288216 — Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · recruiting
- NCT06531395 — A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease · Phase 2 · terminated
- NCT04447469 — Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia · Phase 2, PHASE3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07010159 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kiniksa Pharmaceuticals International, plc
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07010159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing